Zicronapine

Zicronapine
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C22H27ClN2
Molar mass 354.9 g/mol
3D model (JSmol)

Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[1]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[2]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[3]

References

  1. ↑ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
  2. ↑ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
  3. ↑ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Retrieved 18 June 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.